Cambrex's Latest Expansion in Stability Storage
Cambrex, a premier global contract development and manufacturing organization (CDMO), recently announced a significant addition to its operations with the opening of a new state-of-the-art cGMP stability storage facility. This facility is designed to provide enhanced stability storage solutions for the pharmaceutical, medical device, and life sciences industries.
Strategic Location and Advanced Facilities
The new facility is strategically situated in the vicinity of the Research Triangle Park. It features seven ICH stability chambers that meet diverse storage requirements. These chambers cater to a temperature range that includes 2-8°C, 25°C/60%RH, 30°C/65%RH, 30°C/75%RH, and 40°C/75%RH. Moreover, it accommodates storage conditions of both -20°C and ultra-low temperatures ranging from -70°C to -80°C. This location is poised to offer same-day and next-day delivery services throughout the country, which will greatly enhance service delivery capabilities.
CEO Insights on Growth
Tom Loewald, the CEO of Cambrex, expressed his enthusiasm regarding this investment. He noted that after the acquisition of Q1 Scientific in 2022, Cambrex is committed to enhancing its service offerings globally. Loewald emphasized that this milestone is central to the ongoing evolution and expansion of Q1 Scientific's service portfolio.
Complementing Existing Facilities
The new North American facility complements Q1 Scientific’s established operations in locations like Waterford and Liège, thus creating synergies for enhanced service delivery. This facility will not only serve as a storage solution but also support various analytical services critical for the lifecycle of clinical and commercial products.
Expanding Capabilities Across Networks
As Cambrex continues to strengthen its footprint, the company is focused on addressing the increasing demand for outsourced drug development and manufacturing services. With the growth of the pharmaceutical sector, Cambrex is well-positioned to offer comprehensive support to its clientele.
About Cambrex: A CDMO Leader
Cambrex has established itself as a leader in the CDMO landscape, providing comprehensive drug substance development and manufacturing throughout a product's lifecycle. With over four decades of expertise and a global team of around 2,000 dedicated professionals, Cambrex is committed to helping clients navigate the complexities of drug development.
About Q1 Scientific
Q1 Scientific, a Cambrex company, specializes in environmentally controlled stability storage services. Their extensive experience safeguards groundbreaking innovations at state-of-the-art facilities. By leveraging Q1 Scientific's capabilities, pharmaceutical companies can accelerate drug market introductions while minimizing capital expenditure on individualized storage solutions.
Frequently Asked Questions
What is the significance of the new Cambrex facility?
The new facility enhances Cambrex's stability storage capacity, supporting the pharmaceutical sector's growing needs.
Where is the new Cambrex stability storage facility located?
It is strategically placed in the Research Triangle Park region to optimize service delivery.
What types of storage conditions does the facility offer?
The facility includes chambers for a range of temperatures from -80°C to 40°C, catering to various pharmaceutical requirements.
What services does Q1 Scientific provide?
Q1 Scientific offers stability storage and additional analytical services for clinical and commercial products.
How does Cambrex support drug development?
Cambrex provides comprehensive drug substance development and manufacturing services, addressing the full lifecycle of pharmaceuticals.
